Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Hypoplasia Clear all
Completed Phase 2 Interventional Results available

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

NCT00553800
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
bevacizumab, Erlotinib
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
70 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Galloway, New Jersey • Mount Holly, New Jersey • Paoli, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Jul 23, 2026, 7:38 AM EDT
Completed No phase listed Observational

Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer

NCT01255150
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
5
States / cities
Denver, Colorado • Bethesda, Maryland • Kettering, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 1 Interventional Results available

Renal Anhydramnios Fetal Therapy

NCT03101891
View directory record Official record
Conditions
Anhydramnios, Potter Syndrome, Lung Hypoplasia, Multicystic Dysplastic Kidney, Multicystic Renal Dysplasia, Bilateral, Lower Urinary Tract Obstructive Syndrome, Fetal Renal Anomaly
Interventions
Serial amnioinfusions with isotonic fluid, Spinal needle, Isotonic fluid
Procedure · Device · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 7:38 AM EDT
Terminated Phase 1 Interventional

Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer

NCT05062980
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
quaratusugene ozeplasmid, pembrolizumab, docetaxel, ramucirumab, Investigator's Treatment of Choice
Biological · Drug
Lead sponsor
Genprex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Tampa, Florida • New Orleans, Louisiana • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00857025
View directory record Official record
Conditions
Lung Cancer
Interventions
beta-glucan MM-10-001, flow cytometry, laboratory biomarker analysis, questionnaire administration
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Jul 23, 2026, 7:38 AM EDT
Terminated No phase listed Observational

Liquid Biopsy With PET/CT Versus PET/CT Alone in Diagnosis of Small Lung Nodules

NCT05066776
View directory record Official record
Conditions
Lung Cancer, Solitary Pulmonary Nodule, Multiple Pulmonary Nodules
Interventions
Not listed
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma

NCT02583477
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
MEDI4736 in combination with nab-paclitaxel and gemcitabine, MEDI4736 in combination with AZD5069
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Not applicable Interventional

Fetal Surgery for Moderate Left Sided Congenital Diaphragmatic Hernia.

NCT00763737
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Fetal Surgery, Pulmonary Hypoplasia
Interventions
Fetoscopic Endoluminal Tracheal Occlusion
Procedure
Lead sponsor
University Hospital, Gasthuisberg
Other
Eligibility
18 Years and older · Female only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Jul 23, 2026, 7:38 AM EDT
Terminated Phase 1 Interventional

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

NCT03275597
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
Interventions
Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

NCT05134727
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
AZD5055, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 2 Interventional

Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

NCT00112346
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Cetuximab + platinum + gemcitabine, Platinum + Gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
31
States / cities
Mobile, Alabama • Anchorage, Alaska • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Jul 23, 2026, 7:38 AM EDT
Terminated Phase 1 Interventional

(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer

NCT02132403
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
BTH1704, IMPRIME PGG, Gemcitabine
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Phase 1 Interventional

A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects

NCT00955773
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212 plus everolimus
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Jul 23, 2026, 7:38 AM EDT
Recruiting Phase 2 Interventional

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

NCT05068232
View directory record Official record
Conditions
Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Lung Cancer
Interventions
Ablative Radiation, Durvalumab, Etoposide, Carboplatin
Radiation · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 23, 2026, 7:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Liquid Biopsy for Early Non-small Lung Cancer Detection

NCT05462795
View directory record Official record
Conditions
Non Small-cell Lung Cancer
Interventions
Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule, Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection, Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer, Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease
Diagnostic Test
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Jul 23, 2026, 7:38 AM EDT
Recruiting Not applicable Interventional

Amnioinfusion for Fetal Renal Failure

NCT06728228
View directory record Official record
Conditions
Multicystic Dysplastic Kidney, Polycystic Kidney Disease, Fetal Renal Anomaly, Anhydramnios, Potter Syndrome, Lung Hypoplasia, Multicystic Renal Dysplasia, Bilateral, Lower Urinary Tract Obstructive Syndrome, Bilateral Renal Agenesis
Interventions
Amnioinfusion
Other
Lead sponsor
Fetal Care Center, PLLC
Industry
Eligibility
Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Jul 23, 2026, 7:38 AM EDT
Active, not recruiting Not applicable Interventional

Fetoscopic Endoluminal Tracheal Occlusion in Severe Left Congenital Diaphragmatic Hernia

NCT02549820
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia
Interventions
GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 23, 2026, 7:38 AM EDT
Terminated Phase 2 Interventional

Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients Non-Small Lung Cancer

NCT01622621
View directory record Official record
Conditions
Lung Neoplasms
Interventions
Sublobar Resection, Stereotactic Body Radiotherapy (SBRT)
Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Jul 23, 2026, 7:38 AM EDT
Completed Not applicable Interventional

Endobronchial Ultrasound Versus Mediastinoscopy in Patients With Non-Small Cell Lung Cancer (NSCLC)

NCT00559611
View directory record Official record
Conditions
Lung Cancer
Interventions
Endobronchial Ultrasound, Mediastinoscopy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Jul 23, 2026, 7:38 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of FETO in CDH Phase III

NCT07187206
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia, Pulmonary Hypertension
Interventions
FETO, Fetal Endoluminal Tracheal Occlusion
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2033
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 23, 2026, 7:38 AM EDT
Terminated Phase 1Phase 2 Interventional

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

NCT02580708
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Rociletinib, Trametinib
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
St Louis, Missouri • Charlotte, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Jul 23, 2026, 7:38 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

NCT05363280
View directory record Official record
Conditions
Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung
Interventions
AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped
Drug
Lead sponsor
Advenchen Pharmaceuticals, LLC.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
Birmingham, Alabama • Weston, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 7:38 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery

NCT00662311
View directory record Official record
Conditions
Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
vorinostat, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 23, 2026, 7:38 AM EDT
Terminated No phase listed Observational

Afatinib Genomic Landscape

NCT02491775
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-small Lung Cancer
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 4, 2018 · Synced Jul 23, 2026, 7:38 AM EDT